The Identity pacemaker family, which includes the world's smallest dual-chamber pacemaker, provides clinicians with the most advanced pacemaker technology available, including the revolutionary AF ...

LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy ...

Mexico's President Claudia Sheinbaum said on Sunday that reason should prevail a day after her government and the U.S. announced tariffs against one another, raising her fist in the air as she ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December.

Dual agonists are proving to be especially promising ... Second, the medicine everyone thought would take over the industry, Novo Nordisk's CagriSema, did not perform as well as expected in ...

CagriSema – a combination of Novo Nordisk's GLP-1 agonist semaglutide with dual amylin and calcitonin receptor agonist cagrilintide – achieved a 20.4% reduction in weight in the REDEFINE 1 ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot missed ...

Novo issued a press release on December 20, 2024, announcing the disappointing results of its "REDEFINE 1" trial, "a 68-week efficacy and safety trial investigating subcutaneous CagriSema." ...

The plaintiffs, representing investors who purchased Novo Nordisk securities between Nov. 2, 2022, and Dec. 19, 2024, claim the company misrepresented the likelihood of CagriSema achieving at ...